{"url_path":"/sec/cldi/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023140-index.html","accession_number":"0001493152-26-023140","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-023140-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":91,"has_tables":true,"body_markdown":"**Item\n1. Legal Proceedings.**\n\n \n\n**Legal\nProceedings**\n\n \n\nWe\nare subject to litigation and contingencies in the ordinary course of our business, including those related to our business, business\ntransactions, employee-related matters, and other matters. See Item 3-Legal Proceedings to our Form 10-K for the year ended December\n31, 2025, which was filed with the SEC on March 27, 2026. Other than the matters discussed in our annual report on Form 10-K, we are\nnot currently party to any other material legal proceedings that occurred during the first quarter ended March 31, 2026."}